ReviewCureus2022

Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis.

Rahat A Memon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.